Introduction
Mefloquine is a chiral neurotoxic antimalarial agent showing stereoselective brain uptake in humans and rats. Both enantiomers show similar antimalarial activity against Plasmodium falciparum, but the specific neurotoxic effect of separated enantiomers is not known. Mefloquine is a substrate and an inhibitor of the efflux protein P-glycoprotein. We investigated the stereoselective uptake and efflux of mefloquine in mice, and the consequences of the combination with an efflux protein inhibitor, elacridar (GF120918) on its brain transport.
Data and Methods

Chemicals:
• Racemic mefloquine (Hoffmann La Roche, Basel, Switzerland), denoted MQ in the tables and figures.
• P-gp inhibitor GF120918 (elacridar, Glaxo Smith Kline, Marly-leRoi, France): suspended in a PEG600 / water (25/75, v/v) mixture to a final concentration of 1.5 mg.L −1 .
Study design:
• -6 to 7 mice sacrificed at each of the following times after mefloquine treatment: 30 min, 1, 2, 5, 8, 17, 24, 48, 72, 120 , and 168 hours -brain and whole blood samples collected after sacrifice -samples frozen at -20 • C until HPLC analysis Experiments were conducted according to the 'Guidance on the Operation of the Animals (Scientific Procedures) Act 1986'.
Analytical methods:
• Liquid chromatographic equipment -WISP 717+ automatic sample injector -Shimadzu LC10 AV pump -SPD10 AV spectrophotometric detector -Class VP automated software system • Analyses performed at room temperature and at a flow rate of 1.0 mL.min −1 and at 285 nm and 230 nm for the achiral and chiral chromatographies, respectively
Statistical analysis:
• Building of a joint model to describe the pharmacokinetics of the two enantiomers of mefloquine in blood and brain:
-comparison of two-, three-and four-compartment models -absorption and elimination from the blood compartment
• Statistical methods -naive pooling of data (NPD) approach -non linear regression weighted by the empirical variance -model comparison using log-likelihood ratio tests (LRT) and the Akaike criterion -software: R, with library nls2
• Modelling of the pharmacokinetic parameters -θ: parameters for (+)mefloquine in the group without elacridar (reference)
the vector of parameters for (+)mefloquine in the group with elacridar
-θ − GG,k = θ + k × α k × β k × γ k = θ − k × β k × γ k : component θ − k of
the vector of parameters for (-)mefloquine in the group with elacridar
• Comparison of the pharmacokinetic parameters between the two enantiomers and between the two groups -iterative backward procedure starting from full model (all α different from 1) -test each α k one at a time using LRT -remove α k with smallest difference in log-likelihood -repeat same procedure with the β and γ
Results
Model building: Figure 1 : A three-compartment model with zero-order absorption from the injection site was found to best represent the pharmacokinetics of both enantiomers in blood and brain.
BBB
Model equations: • good fit for both enantiomers in the two organs
• adequacy of the model confirmed using diagnostic plots (not shown)
Influence of efflux inhibition on the pharmacokinetics of mefloquine enantiomers in blood and brain: Table 1 : Estimated parameters (and standard errors of estimation in brackets). The values for (+)mefloquine in the group given mefloquine without the inhibitor are taken as reference. α represents the change for (-)mefloquine relative to the reference. β represents the change for (+)mefloquine after the addition of elacridar, relative to the reference. γ represents the differential effect of elacridar on (-)mefloquine with respect to (+)mefloquine.
Mefloquine alone
Pre-treatment with elacridar
76 (9) 0.44 (0.01) 0.25 (0.01) 1.59 (0.05)
Most of the parameters of the model remained unchanged after pretreatment with elacridar, but the transfer rate constant from brain to blood increased for both enantiomers, while the transfer rate constant from tissue to blood decreased. The volumes of distribution in brain were lower by 75% for (+)mefloquine and 60% for (-)mefloquine with elacridar (p<0.001 for both). Because the apparent volumes of distribution in the brain decreased, the efflux clearances of both enantiomers decreased in the presence of the inhibitor (respectively by 60 and 35% for the (+) and (-) enantiomers).
Brain uptake of mefloquine enantiomers: 
Group mefloquine+GF120918
Time (hr)
Brain/blood ratio (g/mL)
Enantiomeric ratios are inverted during the first hour of treatment with elacridar, when compared to the figure without elacridar. When comparing areas under the brain/blood ratio curves, brain-blood ratios for both enaintiomers increased after elacridar, to 1.83 and 1.73 respectively for (+) and (-)mefloquine compared to 0.74 and 1.1 in the absence of elacridar. We also found that the stereoselectivity observed in mefloquine brain uptake without elacridar was almost suppressed by the pre-treatment with elacridar.
Conclusion
(-)Mefloquine had a lower blood and brain apparent volume of distribution and a lower efflux clearance from the brain, resulting in a larger brain/blood ratio compared to (+)mefloquine. Elacridar did not modify blood concentrations or the elimination rate from blood for either enantiomers. However, cerebral AUC of both enantiomers were increased after elacridar administration, with a stronger effect on (+)mefloquine.
After administration of racemic mefloquine in mice, blood and brain pharmacokinetics are stereoselective, (+)mefloquine being excreted from brain more rapidly than its antipode, showing that mefloquine is a substrate of efflux proteins and that mefloquine enantiomers undergo efflux in a stereoselective manner. Moreover, pretreatment with elacridar reduced the brain efflux clearances with a more pronounced effect on (+)mefloquine. †Presenting author email: emmanuelle.comets@bch.ap-hop.paris.fr
